Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Xenetic Biosciences, Inc. XBIO

Healthcare  —  Biotechnology
2.37 (0.10) (4.05%) as of 25 Sep
Market cap
$5.8M
P/E
0.0×
Cash Flow Champion (3y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K
Quarterly (Descending) Quarterly (Ascending) Annual (Descending) Annual (Ascending) TTM (Descending) TTM (Ascending)
Download Excel — free account
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

 0.00 0.00 0.00 0.00
P/S ratio 1.69 1.24 1.92 2.05
P/FCF ratio 0.00 0.00 0.00 0.00
P/Operating CF (7.36) (15.21) (11.45) (7.63)
P/B ratio 1.22 0.50 0.88 1.10
Price to Tangible BV 0.00 0.00 0.00 0.00
EV/Sales 0.26 (1.40) (0.38) 0.07
EV/EBITDA 0.00 1.48 0.50 0.00
EV/Operating CF (0.27) 1.83 0.66 (0.09)
EV/FCF (0.27) 1.83 0.66 (0.09)
Quick Ratio 3.71 8.14 7.67 7.23
Current Ratio 4.56 8.32 7.93 7.43
Net Debt/EBITDA 7.57 12.65 14.63 6.66
Debt/Assets 0.00% 0.00% 0.00% 0.00%
Debt/Equity 0.00 0.00 0.00 0.00
Asset Turnover 0.44 0.39 0.47 0.53
Operating CF/Net income 1.29 0.42 1.18 0.94
Interest Coverage 0.00 0.00 0.00 0.00
Research and Development Expense of Revenue 73.66% 100.93% 81.97% 83.56%
Selling, General and Administrative Expense of Revenue 79.38% 80.37% 80.26% 163.53%
Intangible Assets out of Total Assets 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue 1.55% 1.83% 1.40% 7.87%
Graham Net Nets 0.82 1.92 1.08 0.86
Graham Number 0.00 0.00 0.00 0.00
Earnings Yield (65.29%) (73.27%) (44.78%) (39.86%)
Free Cash Flow Yield (56.09%) (61.87%) (29.63%) (34.61%)
Revenue per Share 0.67 0.45 0.35 0.29
Operating CF per Share (0.43) (0.14) (0.23) (0.38)
Capex per Share 0.00 0.00 0.00 0.00
Free Cash Flow per Share (0.43) (0.14) (0.23) (0.38)
Cash per Share 2.67 4.63 3.21 2.82
Shareholders Equity per Share 2.57 4.35 3.03 2.65
Interest Debt per Share 0.00 0.00 0.00 0.00
Book value per Share 2.57 4.35 3.03 2.65
Free Cash Flow (0.66) (0.24) (0.54) (0.88)
Working Capital 3.96 7.08 6.64 5.76
Net Current Asset Value 3.96 7.08 6.64 5.76
EV/EBIT 0.00 1.48 0.50 0.00
Capex to Sales 0.00 0.00 0.00 0.00
Net Profit Margin (49.65%) (75.57%) (56.56%) (140.74%)
Price to Operating Income 0.00 0.00 0.00 0.00
Other line items
Average Payables 0.41 0.27 0.40 0.33
Average Assets 6.56 7.63 6.85 6.16
Average Common Equity 5.49 6.70 6.04 5.26

Fold the line items

Columns are period end dates